



PEER-REVIEW REPORT

Name of journal: World Journal of Cardiology

Manuscript NO: 47649

Title: One-year outcomes of a NeoHexa sirolimus-eluting coronary stent system with a biodegradable polymer in all-comers coronary artery disease patients: Results from NeoRegistry in India

Reviewer’s code: 03976790

Reviewer’s country: France

Science editor: Fang-Fang Ji

Reviewer accepted review: 2019-04-04 12:25

Reviewer performed review: 2019-04-11 09:38

Review time: 6 Days and 21 Hours

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input checked="" type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer’s expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input checked="" type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input type="checkbox"/> General
			<input checked="" type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

Comments on the manuscript “One-year outcomes of a NeoHexa sirolimus-eluting coronary stent system with a biodegradable polymer in all-comers coronary artery



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

disease patients: Results from NeoRegistry in India” This manuscript is about a survey of patients having received a biodegradable drug-eluting stent (NeoHexa DES), in order to reduce restenosis, with a low rate of stent thrombosis. The purpose was to study the efficiency of NeoHexa DES by comparison with other stents. For that, the authors surveyed a cohort of 129 patients, some of them having co-morbid conditions such as hypertension or diabetes mellitus. The authors concluded NeoHexa could be suggested as an effective stent for the treatment of lesions in the coronary arteries. In the discussion, the authors addressed the economic issue explaining that “cost effectiveness remains a key factor in the decision-making process for patients and health care providers in India” This study can be useful, and could be published. Nevertheless I have several questions. In the discussion, I did not fully understand the sentences: “MACE rates in our study are comparable to previously reported incidence rates for other BP-DES: Endeavor stent (12.9%), NOBORI stent (11%), and Metafor SES (1.6%). Moreover, our results are comparable to the rate observed in the SPIRIT II trial (7.2%).” For NeoHexa, the MACE rate was 4.87%. The authors said that this rate was comparable to other BP-DES, but these were 12.9%, 11%, 1.6%, which is different from 4.86%. The authors also indicated that the results were comparable to the rate observed in the SPIRIT II trial, which is 7.2%. How can these different results be comparable? Please, explain more clearly what it means Minor remark: on Table I: add the number and percentage of females

INITIAL REVIEW OF THE MANUSCRIPT

Google Search:

- The same title
- Duplicate publication
- Plagiarism



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

[Y] No

BPG Search:

[] The same title

[] Duplicate publication

[] Plagiarism

[Y] No